Objectives: The prevalence of linezolid-resistant coagulase-negative Staphylococcus (CoNS) in the MD Anderson Cancer Center rose from 0.6% in 2007 to 5.5% in 2009. The aim of our study was to analyse the relationship between linezolid use and an outbreak of linezolid-resistant CoNS.
Introduction
Coagulase-negative Staphylococcus (CoNS) is the most frequent cause of nosocomial bacteraemia and catheter-related bloodstream infections (CRBSIs). 1 Patients with cancer are at particular risk of CoNS bacteraemia because of the extensive use of central venous catheters and prolonged neutropenia. 
Patients and methods
The laboratory information system provided us with the total number of CoNS isolates between January 2006 and March 2009, as well as their individual linezolid MIC. Isolates for which the MIC was ≥8 mg/L were considered resistant. Antimicrobial susceptibility testing was performed using Vitek Legacy (GPS-110; bioMérieux, Marcy l'Étoile, France) and/or Etest (AB Biodisk, Solna, Sweden Approval was obtained from the Institutional Review Board at the MD Anderson Cancer Center (protocol DR09-0125). The medical records of patients identified as sources of the linezolid-resistant CoNS isolates were reviewed. We used routine quantitative blood cultures on all patient samples. BSI was diagnosed when clinical signs and symptoms of infection accompanied at least two sets of positive blood cultures, and CRBSI when the colony count from a quantitative blood culture drawn from the catheter lumen was at least 3-fold greater than the colony count from a blood culture obtained from a peripheral vein. 1 Blood isolates not meeting these criteria were considered contaminants. We divided other episodes into colonizing events and probable infections, the latter requiring clinical signs and symptoms, isolation from a sterile body fluid or tissue culture and an absolute neutrophil count of ,500 cells/mL. The defined daily dose (DDD) of linezolid was 1200 mg. The Department of Pharmacy Informatics provided us with the quarterly number of linezolid DDDs.
Student's t-test or Wilcoxon rank sum test was used for comparing continuous variables, as appropriate. The incidence rates of linezolid utilization were calculated and compared by a normal-theory test using normal approximation to the binomial distribution. The Poisson method was used to construct the confidence interval (CI) for the incidence rate ratio. All tests were two-sided at a significance level of 0.05. The statistical analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA).
Results

Microbiological data
We identified 35 individual positive cultures corresponding to 27 different events. Eleven isolates recovered from six patients were available for various supplemental investigations. Nine underwent biochemical phenotyping and were identified as Staphylococcus epidermidis. A single strain from each of four patients also underwent partial 16S rRNA gene sequencing, which confirmed the species identification. Among the nine strains analysed by PFGE, all were confirmed to be clonally related. Partial 23S rRNA gene sequencing performed in 10 strains from six patients confirmed the presence of a G2576T mutation in all. Other previously described 23S gene mutations near the 2576 position and associated with linezolid resistance were not observed. Nine isolates tested negative for the presence of the cfr gene using gene-specific PCR.
Patients
Twenty-two patients had 27 events during 25 hospital admissions. Two events occurred in 2006 in one patient and one event in July 2007. The outbreak started in July 2008. Bacteraemia was the most common event (63%). Seven of 17 bacteraemias (41%) were classified as BSI (5) or CRBSI (2) . Six other events were classified as colonization and four as probable infections (Table 1) .
Fourteen patients (64%) had leukaemia and three (14%) had lymphoma. The remaining five had solid tumours and were admitted under five different services. Only four events occurred in the intensive care unit (ICU). All patients received at least one course of linezolid during the 3 months prior to an event for a median duration of 16 days (range 8 -37 days). Twenty-two of 27 events occurred in patients with at least one previous admission to the MD Anderson Cancer Center and five in patients with no previous admission. The median time from admission to positive culture was 3.5 days (range 0 -39 days) for the 22 events having prior admission to the MD Anderson Cancer Center compared with 29 days (range 24 -77 days) for 5 events without a prior admission (P ¼ 0.002).
Institutional linezolid use
The number of linezolid DDDs/100 patient-days was 4 in 2006 and 3.7 in 2007 and increased by 51%, to 5.6, in 2008. The increase in usage started in the second quarter of 2008, prior to the outbreak, and peaked at 7.0 DDDs/100 patient-days in the fourth quarter (Figure 1 ). The leukaemia service had the highest linezolid use, with 34% of linezolid DDDs and 13.3 DDDs per 100 patient-days in 2008, followed by the lymphoma service with 9% of DDDs and 5.8 DDDs per 100 patientdays. The linezolid utilization rate for the leukaemia inpatient service was significantly higher than for the rest of inpatients (13.3 versus 4.3 DDDs/100 patient-days, P,0.0001). The utilization rate ratio was 3.1 (95% CI: 2.96-3.23).
Discussion
This is the first outbreak of linezolid-resistant CoNS reported in a cancer centre. Two previous studies reported outbreaks in an ICU 4, 5 and one in a single ward and its 'feeder' ICU. 6 Only four of our patients were in the ICU, while 16 of 27 events occurred in neutropenic patients, which may reflect a higher infection risk due to the use of central venous catheters and prolonged periods of neutropenia.
We identified the G2576T mutation in all 10 CoNS isolates tested. This is the principal mechanism of linezolid resistance reported among clinical isolates of Enterococcus faecium and Enterococcus faecalis, 7 Staphylococcus aureus 8,9 and S. epidermidis. 4, 5 All nine CoNS isolates tested by PFGE were clonally related, as were the majority of isolates in previous studies. 4 -6 A 51% increase in inpatient linezolid use preceded the outbreak and the leukaemia service, which used three times as much linezolid as the other services, accounted for Mulanovich et al.
two-thirds of patients. The linezolid utilization rate in leukaemia (13 DDDs/100 patient-days) was similar to that reported in the ICU in two previous outbreaks (14 and 15 DDDs/100 patientdays), 5, 6 suggesting that a threshold in selection pressure is necessary for the occurrence of an outbreak. Patients probably acquired the clonal strain by nosocomial transmission from other patients, staff or the environment, 10 given the significantly longer time from admission to event among patients with no previous exposure to the hospital environment. Linezolid administration then selected this strain, as evidenced by the fact that all patients received linezolid prior to an event.
We were unable to determine which units the affected patients were admitted to, and thus could not identify potential sources of the outbreak. The cancer centre has 550 beds, and given the number of different services represented by affected patients, it is unlikely that all or most patients were on the same ward. Empirical use of linezolid has increased in the MD Anderson Cancer Center because of the progressive rise in vancomycin MIC for methicillinresistant S. aureus and concerns about vancomycin-resistant enterococcal infections in colonized febrile neutropenic patients (V. E. Mulanovich, unpublished observation). An antibiotic stewardship programme that monitors antibiotic utilization and provides alternative recommendations may help prevent such outbreaks, especially if utilization thresholds are identified.
Our study had several limitations. This was a retrospective, single-centre investigation that included only a small cohort of patients. We were able to recover only 11 of 27 linezolid-resistant CoNS isolates identified during the study period for supplemental testing. Lastly, epidemiological information on affected patients was not available.
In summary, the establishment of a clonal strain of linezolidresistant CoNS in the MD Anderson Cancer Center was preceded by a 51% increase in the inpatient linezolid utilization rate and 64% of affected patients belonged to the service having the highest linezolid utilization rate. Taken together our observations suggest that increased linezolid use created sufficient selective pressure to favour the appearance and persistence of a resistant clone. The fact that all patients received linezolid prior to an event further supports this conclusion. Inpatient personto-person transmission probably contributed to the outbreak since patients without prior exposure required a longer time in the hospital to experience an event. A linezolid utilization rate of ≥13 DDDs/100 patient-days may be the threshold required to generate an outbreak. Pfizer Global R&D provided PFGE, phenotypic testing and confirmatory susceptibility testing. 
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